Compare STOK & PURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | PURR |
|---|---|---|
| Founded | 2014 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2019 | 2025 |
| Metric | STOK | PURR |
|---|---|---|
| Price | $24.97 | $8.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $46.46 | $22.33 |
| AVG Volume (30 Days) | 782.2K | ★ 11.3M |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.73 | N/A |
| EPS | N/A | ★ 3.21 |
| Revenue | ★ $184,420,000.00 | $9,460,000.00 |
| Revenue This Year | N/A | $484.44 |
| Revenue Next Year | $39.98 | $31.38 |
| P/E Ratio | ★ N/A | $2.68 |
| Revenue Growth | ★ 404.50 | N/A |
| 52 Week Low | $20.32 | $3.01 |
| 52 Week High | $40.22 | $14.76 |
| Indicator | STOK | PURR |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 36.51 |
| Support Level | $24.21 | $7.55 |
| Resistance Level | $33.61 | $9.04 |
| Average True Range (ATR) | 1.33 | 0.61 |
| MACD | 0.35 | -0.29 |
| Stochastic Oscillator | 56.19 | 8.13 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. HSI aims to provide capital-efficient and productive access to the HYPE token for U.S. and institutional investors, generating compounding shareholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement. HSI is positioned to become the HYPE-focused digital asset treasury vehicle capitalizing on Hyperliquid's rapid growth and providing exposure to fastest growing revenue pools in digital assets.